All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How is the definition of high-risk MM evolving?

During the 3rd European Myeloma Network Meeting, the Multiple Myeloma hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, How is the definition of high-risk multiple myeloma (MM) evolving?

How is the definition of high-risk MM evolving?

Paiva begins by explaining how the evolution of defining high-risk MM has been positive over the past few decades, which could lead to significant improvements in how patients are staged in the future. The starting point for defining high-risk MM is a Revised International Staging System (R-ISS) Stage 3. Paiva states that this is effective; however, there is room for improvement, either by increasing the accuracy of risk stratification at baseline or after treatment, for example by assessing additional cytogenetic abnormalities, analyzing tumor burden, and evaluating minimal residual disease.